These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19003539)

  • 1. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of pituitary tumors: somatostatin.
    Tichomirowa MA; Daly AF; Beckers A
    Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodality treatment of pituitary adenomas.
    Oyesiku NM
    Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical approach to pituitary tumors.
    Neggers SJ; van der Lely AJ
    Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome.
    Bronstein MD
    Front Horm Res; 2006; 35():129-134. PubMed ID: 16809928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
    Losa M; Mortini P; Giovanelli M
    Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of pituitary adenoma].
    Chanson P
    Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of pituitary adenomas].
    Mezosi E; Nemes O
    Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA; Ioachimescu AG
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
    Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
    Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
    Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
    Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
    Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
    J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.